# HIGHLIGHTS OF PRESCRIBING INFORMATION

**These highlights do not include all the information needed to use XOLREMDI™ safely and effectively. See full prescribing information for XOLREMDI™.**

**XOLREMDI™ (mavorixafor) capsules, for oral use Initial U.S. Approval: 2024**

## INDICATIONS AND USAGE

XOLREMDI is a CXC chemokine receptor 4 antagonist indicated in

patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase

the number of circulating mature neutrophils and lymphocytes. (1)

## DOSAGE AND ADMINISTRATION

- Recommended dosage:
  - Weight more than 50 kg: 400 mg orally once daily (2)
  - Weight less than or equal to 50 kg: 300 mg orally once daily (2)
- Administer XOLREMDI on an empty stomach after an overnight fast, and at least 30 minutes before food. (2)

## DOSAGE FORMS AND STRENGTHS

Capsules: 100 mg mavorixafor (3)

## CONTRAINDICATIONS

Use with drugs highly dependent on CYP2D6 for clearance. (4, 7.2)

## WARNINGS AND PRECAUTIONS

- Embryo-fetal toxicity: Expected to cause fetal harm. Advise women of reproductive potential to use effective contraception. (5.1, 8.1, 8.3)
- QTc Interval Prolongation: Correct any modifiable risk factors, assess QTc at baseline and monitor QTc during treatment as clinically indicated. XOLREMDI dose reduction or discontinuation may be required due to drug-drug interactions. (5.2) ![](Aspose.Words.c0d57741-1e92-457a-a6ee-a45779083e95.001.png)
